Eli Lilly’s rapid growth driven by GLP-1 drugs faces scrutiny as the company prepares for new product launches amid high valuations, with investors keenly awaiting Q2 results for further signals of sustained momentum.
Eli Lilly may have delivered only modest share price gains so far this year, but the company’s underlying momentum still looks formidable. According to Yahoo Finance, the drugmaker has been lifted by the extraordinary uptake of its GLP-1 medicines, even as investors wait for the next leg of growth to arrive.
That growth was evident in the first quarter of 2026, when revenue jumped 56% year on year to $19.8 billion. Yahoo Finance reported that Mounjaro sales surged 125% to $8.7 billion, while Zepbound rose 80% to $4.1 billion, underscoring just how central tirzepatide has become to Lilly’s business. The company responded by raising full-year revenue guidance to between $82 billion and $85 billion.
The bigger question for investors is whether Lilly can keep the story moving once the initial wave of demand for its current obesity and diabetes franchises matures. Analysts cited by Yahoo Finance point to retatrutide, the company’s experimental triple-agonist, as the next major catalyst. Early phase 3 data released last month indicated substantial weight loss in patients with obesity and related conditions, including type 2 diabetes and cardiovascular disease. Lilly is expected to file for regulatory approval early next year, which could put a launch into 2027.
Another important development is Foundayo, Lilly’s newly approved oral GLP-1 treatment for weight management. Yahoo Finance reported that the FDA has cleared the drug and that it is already being distributed through LillyDirect, with broader availability planned. In clinical testing, patients on the highest dose lost an average of 12.4% of body weight, giving the company a second obesity-focused platform beyond injections.
Even so, valuation remains a concern. Yahoo Finance noted that Lilly trades on roughly 34 times earnings, a premium that leaves little room for disappointment. With second-quarter results due on 5 August, investors will be watching closely for any update on demand, guidance, and the pace at which Foundayo is scaling. For now, the case for the stock rests on whether Lilly can turn a successful GLP-1 franchise into a much longer growth cycle.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
